Investigators from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified five autophagy-inhibiting compounds (WX8 family) through a high-throughput screening. The NICHD seeks licensees and/or co-development partners for methods to treat cancer by administering these autophagy-inhibiting compounds.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licenses and/or co-development partners for methods of treating cancer by administering PIKFYVE inhibitors and P38 MAP kinase inhibitors.
GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). NICHD seeks parties to license this invention towards commercialization.
In collaboration with the National Cancer Institute (NCI), researchers at The Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD) have discovered monoclonal antibodies that bind to matrilin-3, a protein specifically expressed in cartilage tissue, that could be used for treating or inhibiting growth plate disorders, such as a skeletal dysplasia or short stature. The monoclonal antibodies can also be used to target therapeutic agents, such as those for anti-arthritis, to cartilage tissue. NICHD seeks statements of capability or interest from parties interested in collaborative research to co-develop, evaluate, and/or commercialize treatment of skeletal disorders using targeting antibodies.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licensing and/or co-development of two novel gene therapy vectors for the treatment of glycogen storage disease type Ib (GSD-Ib).
The Section on Translational Neuroscience of NICHD seeks parties interested in licensing and/or collaborative research to co-develop this therapeutic management of Menkes Disease and related copper transport disorders.